Search

Your search keyword '"van Alphen, L."' showing total 437 results

Search Constraints

Start Over You searched for: Author "van Alphen, L." Remove constraint Author: "van Alphen, L."
437 results on '"van Alphen, L."'

Search Results

151. Portrait of a leading vaccinologist: dedicated to meningitis and respiratory tract infections.

152. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome.

153. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.

154. 16th International Pathogenic Neisseria Conference: recent progress towards effective meningococcal disease vaccines.

155. Meningococcal B vaccine development and evaluation of efficacy.

156. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs.

157. A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis.

158. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

159. Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design.

160. Characterization of genetic and phenotypic diversity of invasive nontypeable Haemophilus influenzae.

161. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.

162. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.

163. PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

164. A Neisserial autotransporter NalP modulating the processing of other autotransporters.

165. Mapping the binding domains on meningococcal Opa proteins for CEACAM1 and CEA receptors.

166. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.

167. Lipoprotein signal peptidase of Streptococcus suis serotype 2.

168. Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations.

169. Involvement of lipooligosaccharides of Haemophilus influenzae and Neisseria meningitidis in defensin-enhanced bacterial adherence to epithelial cells.

170. Mucin in middle ear effusions inhibits attachment of Haemophilus influenzae to mucosal epithelial cells.

171. Diagnosis of infection.

172. New strains of bacteria and exacerbations of COPD.

173. Conformational analysis of opacity proteins from Neisseria meningitidis.

174. Response regulator important in pathogenesis of Streptococcus suis serotype 2.

175. Expression of foreign LpxA acyltransferases in Neisseria meningitidis results in modified lipid A with reduced toxicity and retained adjuvant activity.

176. Distribution of environmentally regulated genes of Streptococcus suis serotype 2 among S. suis serotypes and other organisms.

177. Genes of non-typeable Haemophilus influenzae expressed during interaction with human epithelial cell lines.

178. Contribution of fibronectin-binding protein to pathogenesis of Streptococcus suis serotype 2.

179. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

180. Roles of interleukin-6 and macrophage inflammatory protein-2 in pneumolysin-induced lung inflammation in mice.

181. In vivo expression of Neisseria meningitidis proteins homologous to the Haemophilus influenzae Hap and Hia autotransporters.

182. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.

183. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity.

184. Contributions of Neisseria meningitidis LPS and non-LPS to proinflammatory cytokine response.

185. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.

186. The variable P5 proteins of typeable and non-typeable Haemophilus influenzae target human CEACAM1.

187. Construction of porA Mutants.

188. Outer membrane protein vesicle vaccines for meningococcal disease.

189. Serological characterization.

190. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations.

191. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease.

192. Stimulation of bacterial adherence by neutrophil defensins varies among bacterial species but not among host cell types.

193. Interaction of clinical isolates of nonencapsulated Haemophilus influenzae with mammalian extracellular matrix proteins.

194. In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components.

195. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.

196. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity.

197. Variable numbers of tandem repeat loci in genetically homogeneous Haemophilus influenzae strains alter during persistent colonisation of cystic fibrosis patients.

198. Variation in the composition and pore function of major outer membrane pore protein P2 of Haemophilus influenzae from cystic fibrosis patients.

200. Stimulation of the adherence of Haemophilus influenzae to human lung epithelial cells by antimicrobial neutrophil defensins.

Catalog

Books, media, physical & digital resources